Literature DB >> 11763473

A nifedipine coground mixture with sodium deoxycholate. II. Dissolution characteristics and stability.

H Suzuki1, M Ogawa, K Hironaka, K Ito, H Sunada.   

Abstract

Nifedipine is a poorly water soluble drug that demonstrates low bioavailability. In a previous study, a coground mixture of nifedipine with sodium deoxycholate (DCNa), a bile salt, immediately produced colloidal particles when dispersed in water. In this study, the effect of the weight fraction of DCNa, grinding time, dissolution media, and storage conditions on colloidal particle formation in solution was investigated. The coground mixture was prepared with a vibration rod mill, and its solid state was characterized using powder X-ray diffraction. A laser diffraction particle size analyzer was used to determine the particle size distribution curve in water. The size of particles formed in solution decreased with an increase in the weight fraction of DCNa and grinding time. A nifedipine-DCNa (1:2 w/w) mixture coground for 30 min was used in the experiments. Colloidal particle formation from the coground mixture was also observed in dissolution media of water and a pH 6.8 buffer solution at 37 degrees C. Most precipitates passed through a filter with a pore size of 0.8 microm, but the particle size distribution in water was different from that in the pH 6.8 buffer solution. DCNa exhibited not only micellar solubilization for drug crystals, but also a retarding effect on drug crystal growth in a supersaturated solution. The latter effect could serve to form colloidal particles in solution. When stored under 75% relative humidity at 40 degrees C for 1 month, the amorphous coground mixture crystallized, and the particle size in water markedly increased. Therefore, the weight fraction of DCNa, grinding time, dissolution media, and humidity during storage influence the dissolution characteristics of nifedipine from a coground mixture.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11763473     DOI: 10.1081/ddc-100107676

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  6 in total

1.  Molecular interaction among probucol/PVP/SDS multicomponent system investigated by solid-state NMR.

Authors:  Adchara Pongpeerapat; Kenjirou Higashi; Yuichi Tozuka; Kunikazu Moribe; Keiji Yamamoto
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

2.  Phase transited asymmetric membrane floating nanoparticles: a means for better management of poorly water-soluble drugs.

Authors:  Betty Annie Samuel; Bassim I Mohammed; Anil K Philip
Journal:  Daru       Date:  2021-08-20       Impact factor: 4.088

3.  Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation.

Authors:  Rofida Albash; Aly A Abdelbary; Hanan Refai; Mohamed A El-Nabarawi
Journal:  Int J Nanomedicine       Date:  2019-03-15

4.  Mechanically Robust Gastroretentive Drug-Delivery Systems Capable of Controlling Dissolution Behaviors of Coground β-Lapachone.

Authors:  Hyeongmin Kim; Chung-Lyol Lee; Seohyun Lee; Tae Jin Lee; Iqra Haleem; Younghong Lee; Na Jung Hwang; Kyusun Shim; Dohyun Kim; Jaehwi Lee
Journal:  Pharmaceutics       Date:  2019-06-10       Impact factor: 6.321

5.  Formation and Physico-Chemical Evaluation of Nifedipine-hydroxypropyl-β-cyclodextrin and Nifedipine-methyl-β-cyclodextrin: The Development of Orodispersible Tablets.

Authors:  Emma Adriana Ozon; Marian Novac; Daniela Gheorghe; Adina Magdalena Musuc; Mirela Adriana Mitu; Iulian Sarbu; Valentina Anuta; Adriana Rusu; Simona Petrescu; Irina Atkinson; Dumitru Lupuliasa
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-12

6.  Mitigation of Rheumatic Arthritis in a Rat Model via Transdermal Delivery of Dapoxetine HCl Amalgamated as a Nanoplatform: In vitro and in vivo Assessment.

Authors:  Heba Farouk Salem; Mohamed Mahmoud Nafady; Rasha Mostafa Kharshoum; Omnia Ahmed Abd El-Ghafar; Hanan Osman Farouk
Journal:  Int J Nanomedicine       Date:  2020-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.